Hydra Biosciences, Inc., a leader in the field of transient receptor potential channel modulation, and Boehringer Ingelheim announced that they have entered into a worldwide research collaboration and license agreement to identify small-molecule transient receptor potential inhibitors, to focus on renal disease treatments.
Hydra Biosciences, a biopharmaceutical company based in Cambridge, MA, develops drugs to treat several conditions involving ion channels.
Hydra’s high-throughput screening platforms and integrated pharmacology and chemistry infrastructure allow the company to identify and develop drug candidates that address unmet medical needs.
“This partnership between Boehringer Ingelheim and Hydra Biosciences provides an excellent opportunity to maximize the potential of novel targets that may offer meaningful improvements in the treatment of chronic kidney diseases and other related diseases and disorders,” said Russell Herndon, president and CEO of Hydra Biosciences.
“Renal diseases and disorders are of increasing importance to Boehringer Ingelheim as part of our CardioMetabolic Diseases Research area, and our dedicated renal disease research unit based in Ridgefield, CT, is constantly expanding its network of partnerships in this field,” said Michel Pairet, senior corporate vice president of research and nonclinical development at Boehringer Ingelheim. “This new collaboration agreement with Hydra Biosciences reflects the importance and value Boehringer Ingelheim places in developing strong research partnerships to discover new treatments for renal diseases and related disorders.”
The companies’ researchers will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an undisclosed upfront payment and is eligible to receive milestone payments and tiered royalty payments based on future product sales.
